Additionally, the publication in the Lancet Neurology and the opinions printed in same issue by Langbehn, an impartial scientist are compelling and supportive of the trial and the results from REACH2HD. Especially when you look at the very statistically significant and near repetition of the TMTB results from REACH2HD and 2A trials. Function is very important to HD sufferers as exhibited by their comments during the FDA Patient-focused 9-2015 meeting and their written comments to FDA.
VP of Business Development, page-16
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $2.401K | 800.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 77 | 110142186 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 150940914 | 62 |
View Market Depth
| Last trade - 10.20am 08/11/2024 (20 minute delay) ? |
| ATH (ASX) Chart |